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Abstract
Background: Despite being a mainstay for treating superficial bladder carcinoma and a promising
agent for interstitial cystitis, the precise mechanism of Bacillus Calmette-Guerin (BCG) remains
poorly understood. It is particularly unclear whether BCG is capable of altering gene expression in
the bladder target organ beyond its well-recognized pro-inflammatory effects and how this relates
to its therapeutic efficacy. The objective of this study was to determine differentially expressed
genes in the mouse bladder following chronic intravesical BCG therapy and to compare the results
to non-specific pro inflammatory stimuli (LPS and TNF-α). For this purpose, C57BL/6 female mice
received four weekly instillations of BCG, LPS, or TNF-α. Seven days after the last instillation, the
urothelium along with the submucosa was removed from detrusor muscle and the RNA was
extracted from both layers for cDNA array experiments. Microarray results were normalized by
a robust regression analysis and only genes with an expression above a conditional threshold of
0.001 (3SD above background) were selected for analysis. Next, genes presenting a 3-fold ratio in
regard to the control group were entered in Ingenuity Pathway Analysis (IPA) for a comparative
analysis in order to determine genes specifically regulated by BCG, TNF-α, and LPS. In addition,
the transcriptome was precipitated with an antibody against RNA polymerase II and real-time
polymerase chain reaction assay (Q-PCR) was used to confirm some of the BCG-specific
transcripts.
Results: Molecular networks of treatment-specific genes generated several hypotheses regarding
the mode of action of BCG. BCG-specific genes involved small GTPases and BCG-specific
networks overlapped with the following canonical signaling pathways: axonal guidance, B cell
receptor, aryl hydrocarbon receptor, IL-6, PPAR, Wnt/β-catenin, and cAMP. In addition, a specific
detrusor network expressed a high degree of overlap with the development of the lymphatic
system. Interestingly, TNF-α-specific networks overlapped with the following canonical signaling
pathways: PPAR, death receptor, and apoptosis. Finally, LPS-specific networks overlapped with the
LPS/IL-1 mediated inhibition of RXR. Because NF-kappaB occupied a central position in several
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networks, we further determined whether this transcription factor was part of the responses to
BCG. Electrophoretic mobility shift assays confirmed the participation of NF-kappaB in the mouse
bladder responses to BCG. In addition, BCG treatment of a human urothelial cancer cell line (J82)
also increased the binding activity of NF-kappaB, as determined by precipitation of the chromatin
by a NF-kappaB-p65 antibody and Q-PCR of genes bearing a NF-kappaB consensus sequence. Next,
we tested the hypothesis of whether small GTPases such as LRG-47 are involved in the uptake of
BCG by the bladder urothelium.
Conclusion:  As expected, BCG treatment induces the transcription of genes belonging to
common pro-inflammatory networks. However, BCG also induces unique genes belonging to
molecular networks involved in axonal guidance and lymphatic system development within the
bladder target organ. In addition, NF-kappaB seems to play a predominant role in the bladder
responses to BCG therapy. Finally, in intact urothelium, BCG-GFP internalizes in LRG-47-positive
vesicles.
These results provide a molecular framework for the further study of the involvement of immune 
and nervous systems in the bladder responses to BCG therapy.
Background
Intravesical Bacillus Calmette-Guerin (BCG) is best
known as the most effective agent for the treatment of
high-grade superficial bladder cancer [1-3]. In this con-
text, BCG is used to reduce both the recurrence rate of
bladder tumor and to diminish the risk of its progression
[1,2]. As an adjunct to transurethral resection, BCG is the
treatment of choice for urothelial carcinoma in-situ (CIS)
and is commonly used for recurrent or multi-focal Ta and
high grade T1 bladder lesions [4,5]. BCG also has been
tested as a promising option for treatment of interstitial
cystitis [6].
It is not clear how BCG alters the course of cystitis or can-
cer progression. One theory is that intravesical BCG cor-
rects an aberrant immune imbalance in the bladder,
leading to long-term symptomatic improvement [1].
Recently, the susceptibility to BCG was correlated with
polymorphisms of the human NRAMP1 gene [7], provid-
ing interesting insights into the complexity of the genom-
ics of BCG immunotherapy [8].
That BCG causes an extensive local inflammatory reaction
in the bladder wall is well acknowledged [9]. Of this, the
massive appearance of cytokines in the urine of BCG-
treated cancer patients stands out [9]. Activated lym-
phocytes and macrophages are the most likely sources of
these cytokines, but at present other cellular sources such
as urothelial cells cannot be ruled out [9]. BCG is internal-
ized and processed by neutrophils [10], professional anti-
gen-presenting cells and urothelial tumor cells, resulting
in altered gene expression and secretion of particular
cytokines [9]. It was suggested that the effectiveness of
BCG treatment is determined by two processes: an inflam-
matory one, followed by a delayed type of hypersensitivity
response [11]. Others proposed three distinct phases in
the immune response to BCG. In phase 1, BCG adheres to
the urothelium via interaction between the bacterial anti-
gen 85 complex and fibronectin [5,12] and urothelial
cells. In addition to fibronectin, it has been suggested that
toll-like receptors (TLRs) -2 and -4, present in immune
cells, mediate BCG-induced immune responses [13-15].
Once internalized, BCG is processed both by professional
antigen-presenting cells and urothelial cells, resulting in
an altered gene expression [9]. This phase corresponds to
the early release of so-called inflammatory cytokines (IL-
1, IL-6, and IL-8 in humans) which may be responsible for
certain adverse effects. Phase 2 consists of recognition of
bacterial antigens by CD4+ lymphocytes, which release
mainly IL-2 and IFN-γ (TH1 response). This cell activation
leads to phase 3, consisting of amplification of cytotoxic-
populations: CD8+  T cells, gamma-delta lymphocytes,
macrophages, and natural killer (NK) cells. All of these
cells also release cytokines that may further regulate the
BCG response [16].
More recently, studies have shown that mycobacterial
DNA contains high amounts of CpG motifs. These CpG
motifs induce tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) expression [17] and increase
serum levels of mouse keratinocyte-derived chemokine
(KC), a functional homolog of human interleukin IL-8
[18]. Urinary TRAIL levels were initially undetectable in
BCG therapy patients but levels increased after subse-
quent treatments. More importantly, patients that
responded to BCG therapy had significantly higher urine
TRAIL levels, which killed bladder tumor cells in vitro ver-
sus non-responders. Given this data, it was proposed that
TRAIL also plays a role in BCG-induced anti-tumor effects
[17]. Nevertheless, BCG's exact mechanism of therapeutic
action remains poorly understood. Although systemicBMC Immunology 2008, 9:4 http://www.biomedcentral.com/1471-2172/9/4
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reactions have been reported, a more likely scenario is that
exposure to BCG results in a local immune response with
massive inflammation [5]. This inflammatory infiltrate
makes it difficult to analyze the direct effects of BCG on
the urinary bladder in BCG treated patients. In order to
determine the differences in bladder mucosa and detrusor
gene regulation in response to BCG in comparison to
those elicited by other inflammatory stimuli (LPS and
TNF-α) we sought to differentiate BCG-specific effects
from the generalized inflammatory reactivity. For this pur-
pose, we used the C57BL/6 mice because our previous
work already defined the time-course of bladder inflam-
mation and urinary cytokine release in response to intra-
vesical instillation of BCG, TNF-α, and LPS [19].
Results
Specific Genes
Mucosal and detrusor genes were classified as BCG-, TNF-
, or LPS-specific genes and their numbers are represented
in the Venn diagram of Figure 1. Genes that were altered
by more than one treatment were called unspecific and are
not represented (blank spaces in the Venn Diagram). The
list of TNF-, LPS-, and BCG-specific genes is presented in
Tables S1, S2, and S3, respectively (Additional files 1, 2,
and 3 respectively).
Comparative analysis of networks
Next, the expression values (ratio = Treated/Saline) and
the gene bank accession number for each specific genes
was entered in the IPA database as focus genes. The inter-
pretation of these datasets in the context of biological
processes, pathways, and molecular networks composed
the IPA core analysis. Results of the core analysis for BCG-
, LPS-, and TNF-α-specific genes in the mucosa and detru-
sor were entered in a core comparison analysis which
allows comparison of changes in biological states across
the different treatments and to highlight which biological
processes and/or diseases are relevant to each of the treat-
ments. IPA computed a score for each network according
to the fit of the set of supplied focus genes (BCG-, TNF-,
and LPS-dependent genes). These scores, derived from p
values, indicated the likelihood that focus genes belong-
ing to a network versus those obtained by chance. A score
>2 indicates a ≥ 99% confidence that a focus gene network
was not generated by chance alone [20]. Only networks
with a score above 20 were selected for further analysis.
Detrusor BCG-specific networks. From the isolated
detrusor muscle, 92 genes were found to be BCG-specific
and their networks are represented in Figures 2, 3, 4. Net-
work 1 (Figure 2A) received the highest score (50) and
assembles 24 BCG-specific genes. This network has in a
central position: NF-kappaB, MAP kinase (a NGF/EGF
dependent kinase), PI3 kinase, and Jnk and overlays with
the axonal guidance canonical pathway (GNB5, GNB4,
GNG3, RALBP1, integrin, rac protein, PI3K, PRKD1,
PRKCE, PKC, and PDGF). In this pathway, 3 members of
the small GTPase family were up-regulated and found
upstream of MAP kinase signaling. In contrast, members
of the ATPase family such as DEAH (DHX15) were down-
regulated. In addition, a gene encoding the mitogen-acti-
vated protein kinase kinase kinase 8 was found linking the
NF-kappaB, MAP kinase, and ERK kinase (Mek) pathways.
A group of genes encoding members of the integrin path-
way was also observed and included: PLAUR (plasmino-
gen activator, urokinase receptor), WISP2, VCAM1, and
ITGAM (integrin alpha m). This network was correlated
with the following functions: cell-to-cell signaling, hema-
tological system development and function, and immune
and lymphatic system development and function. Net-
work 2 (Figure 2B) presents IL4 and TGFbeta1 in a central
position and overlays with a series of canonical pathways
(too many to be described). A small GTPase, interferon-
inducible, guanylate binding protein 2 (GBP2) was found
in this pathway downstream of IL-4 [21]. In addition, sev-
eral of the BCG-specific genes are related with calcium and
β-estradiol metabolism, including: WISP2, ROCK1 (Rho-
GTP binding), MYO1B, S100A13, and CD55. This net-
work was correlated with the following functions: cell-to-
cell signaling, cellular movement, and cancer. Network 3
(Figure 3A) presents Akt and p38MAPK in central posi-
tions and overlaps with the B cell receptor canonical path-
way (Calmodulin, CSK, P38MAPK, Akt, and CD22).
Interestingly, this network presents genes of neuronal ori-
gin such as CDH2 (N-cadherin), DNAJ35 (a Hsp40
homolog found in axons), and CTNND2 (catenin or neu-
ral plakophilin-related protein). In addition, two genes
upstream of Histone H3 were up-regulated by BCG: AATF
(an apoptosis antagonist transcription factor) and
ARHGEF7 (Rho guanine nucleotide exchange factor). This
network was correlated with the following functions:
inflammation, dermatological diseases, and cellular
growth and differentiation. Network 4 (Figure 3B)
presents TNF-α in a central position and overlays with a
series of canonical pathways (too many to be described).
PADI3 was found highly up-regulated (dark red) and
Venn diagram indicating the numbers of Mucosal and Detru- sor genes that were classified as BCG-, TNF-, or LPS-specific Figure 1
Venn diagram indicating the numbers of Mucosal and Detru-
sor genes that were classified as BCG-, TNF-, or LPS-specific.
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encodes peptidyl arginine deiminase, type III, a target of
TP53. Genes downstream of TNF-α includes a pro-inflam-
matory cytokine IL-17, RAET1B (retinoic acid early tran-
script beta), HLA-DRB1 (a major histocompatibility
complex, class II), RFX5 (an MHC regulatory factor), and
CD55 (a member of the complement system). In this net-
work, TFEB was up-regulated and this gene encodes a tran-
scriptional factor expressed in the urothelium and
detrusor muscle that responds to bladder inflammation
[22]. This network was correlated with the following func-
tions: cancer, cell-to-cell signaling, and immunological
disease. Network 5 (Figure 4A) presents FOS, IL-6, and
Networks 1 and 2. BCG-induced specific genes in the detrusor muscle Figure 2
Networks 1 and 2. BCG-induced specific genes in the detrusor muscle. Microarray results were normalized by a 
robust regression analysis and only genes with an expression above a conditional threshold of 0.001 (3 SD above background) 
were selected for analysis. Next, genes presenting a 3-fold ratio in regard to the control group were entered as focus genes in 
Ingenuity Pathway Analysis (IPA) for a core analysis which put the datasets in the context of biological processes, pathways, and 
molecular networks.
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Networks 3 and 4. BCG-induced specific genes in the detrusor muscle Figure 3
Networks 3 and 4. BCG-induced specific genes in the detrusor muscle. Microarray results were normalized by a 
robust regression analysis and only genes with an expression above a conditional threshold of 0.001 (3 SD above background) 
were selected for analysis. Next, genes presenting a 3-fold ratio in regard to the control group were entered as focus genes in 
Ingenuity Pathway Analysis (IPA) for a core analysis which put the datasets in the context of biological processes, pathways, and 
molecular networks.
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the transcription factor E2F1 in a central position and
overlays with the aryl hydrocarbon receptor canonic path-
way (GSTA5, GSTP1, GSTM1, Rar [all trans retinoic acid
receptor], FOS, IL-6, E2F1, and retinoic acid). Interest-
ingly, a group of genes involved in retinoic acid metabo-
lism was highlighted, and included: ILF3 (interleukin
enhancer binding factor 3), HOXD1 (homeobox D1),
SOX, MID2, and GSTA5 (glutathione S-transferase A5).
This network was correlated with the following functions:
cellular signaling, cancer, and cellular growth and prolif-
eration. Network 6 presents STAT3 and JUN in a central
position and overlaps with the IL-6 canonic pathway
(IL6R; JUN; Ck2; STAT3), (Figure 4B). A small GTPase
(GNA14) was found upstream of STAT3. Interestingly, a
group of genes involved in the dihydrotestosterone
metabolism was highlighted: LCN5, SLC16A7, and
SMARCC1. In addition, genes involved in the regulation
of MMP2 (gelatinase A), such as MMP15 were found
down-regulated by BCG treatment. Downstream of
CTNNB1 (catenin), SEMA5A, an axon guidance molecule,
was down-regulated by BCG. This network was correlated
with the following functions: cellular development, devel-
opment disorder, and cellular growth and proliferation.
Mucosal BCG-specific networks
Network 7 (Figure 5A) presents NF-kappaB and HRAS in
central positions and overlays with the PPAR canonic
pathway (NF-kappaB, NRIP1, NR1H3, HRAS, Hsp90).
Genes correlated with NF-kappaB include INDO (a
indoleamine-pyrrole 2,3 dioxygenase that represents a tar-
get for IFN-γ), which is responsible for regulating tryp-
tophan metabolism, FCER2 (Fc fragment of IgE receptor),
MAST2 (member of IL-4 signalling, a microtubule associ-
ated serine/threonine kinase), GRIA4 (glutamate recep-
tor), and LTA (member of TNF super family). In this
pathway, IGFBP3, SMAD6, and BSG were found to be
down-regulated. This pathway was correlated with the fol-
lowing functions: gene expression, cancer, and cell cycle.
Network 8 (Figure 5B) has TGFB1, NOTCH1, and TNF-α
in a central position, and overlaps with the Wnt/β-catenin
canonic pathway (GNAQ; TGFB1, NOTCH1, SOX4, and
retinoic acid). Genes highly up-regulated (dark red)
included: NOS (neuronal endothelium-derived relaxation
factor-forming enzyme), and SPR (an aldo-keto reductase
that is part of the arginine metabolism). Additional genes
of the TNF-α pathway included the pro-inflammatory
cytokine IL-17 and caspase 1. Another small GTPase
(GNB5) was part of this pathway. In addition, several
genes involved in retinoic acid metabolism were high-
lighted, including: GZMA (granzyme A), and HEPBP1 (a
heme binding protein). This pathway was correlated with
the following functions: cellular development, connective
tissue development and function, skeletal muscular sys-
tem development and function. Network 9 (Figure 6) has
IL-6, STAT5, and SRC in a central position. This pathway
overlaps with the cAMP-canonical pathway (HTR4, SRC;
PDE4A; AKAP8; and AKAP1) and G-Protein canonical
pathway (SRC; AKT2; HTR4; and PDE4A). Highly up-reg-
ulated genes (dark red) included: AKAP8 (a kinase anchor
protein 8) and ZP3 (zona pellucida glycoprotein 3).
Networks 5 and 6. BCG-induced specific genes in the detrusor muscle Figure 4
Networks 5 and 6. BCG-induced specific genes in the detrusor muscle. Microarray results were normalized by a 
robust regression analysis and only genes with an expression above a conditional threshold of 0.001 (3 SD above background) 
were selected for analysis. Next, genes presenting a 3-fold ratio in regard to the control group were entered as focus genes in 
Ingenuity Pathway Analysis (IPA) for a core analysis which put the datasets in the context of biological processes, pathways, and 
molecular networks.
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Networks 7 and 8. BCG-induced specific genes in the bladder mucosa Figure 5
Networks 7 and 8. BCG-induced specific genes in the bladder mucosa. Microarray results were normalized by a 
robust regression analysis and only genes with an expression above a conditional threshold of 0.001 (3 SD above background) 
were selected for analysis. Next, genes presenting a 3-fold ratio in regard to the control group were entered as focus genes in 
Ingenuity Pathway Analysis (IPA) for a core analysis which put the datasets in the context of biological processes, pathways, and 
molecular networks.
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Networks 9. BCG-induced specific genes in the bladder mucosa Figure 6
Networks 9. BCG-induced specific genes in the bladder mucosa. Microarray results were normalized by a robust 
regression analysis and only genes with an expression above a conditional threshold of 0.001 (3 SD above background) were 
selected for analysis. Next, genes presenting a 3-fold ratio in regard to the control group were entered as focus genes in Inge-
nuity Pathway Analysis (IPA) for a core analysis which put the datasets in the context of biological processes, pathways, and 
molecular networks.
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Down-regulated genes included LYZ (a lysozyme) and
TXNL1 (thioredoxin-like 1, a regulator of insulin). This
pathway was correlated with the following functions: cel-
lular growth and proliferation, cancer, and cell-to-cell sig-
naling.
TNF-α-specific genes
Network 10 presents detrusor genes specifically up-regu-
lated by TNF-α (Figure 7A). This network presents TNF-α,
NF-kappaB, and TGFB3 in central positions and overlays
with PPAR signaling canonical pathway (TNF-α; PDGF;
PDGFR, PDGF Ab; PDGFRA; and NF-kappaB). Genes
highly up-regulated (dark red) included: PDGFB, and
MC5R (melanocortin 5 receptor). OPRS1 (opioid recep-
tor, sigma) was down-regulated by TNF-α. This pathway
was correlated with the following functions: cancer, post-
translational modification, and cell death. Network 11
presents mucosal genes specifically up-regulated by TNF-
α (Figure 7B). This network has TNF-α, IFNγ, IL-4, IL-6,
and MAPK1 in central positions and overlays with the
death receptor canonical pathway (IFNγ, TNF-α, IKBKB,
CASP3, CASP8, and TNFRSF1DB) and the apoptosis sign-
aling canonical pathway (TNF-α, IKBKB, CASP3, CASP8,
and MAPK1). The gene encoding a sodium channel
(SCNN1B) was found highly up-regulated (dark red). This
pathway was correlated with the following functions: can-
cer, cell death, and reproductive system disease.
LPS-specific genes
Network 12 (Figure 8A) presents mucosal genes specifi-
cally up-regulated by LPS and has NF-kappaB, MAPK8,
JUN, IL-1β, and IFNγ in central positions. This network
overlaps with the canonical pathway of LPS/IL-1-medi-
ated inhibition of RXR receptors (JUN, MAPK8, SLC10A1
[solute carrier family 10], NR0B2 [nuclear receptor sub-
family 0, group B, member 2], ABCB11 [ATP-binding cas-
sette], IL-1B, SCARB1 [scavenger receptor class B, member
1], and NR1H2 [nuclear receptor subfamily 1, group H,
member 2]). Genes highly up-regulated included: NR0B2,
MMP12, PTPN18 (protein tyrosine phosphatase, non-
receptor type 18), and RASSF1 (Ras association [RalGDS/
AF-6] domain family 1). This pathway was correlated with
the following functions: cell signaling, genetic disorder,
and hepatic system disease. Network 13 (Figure 8B)
presents detrusor genes specifically up-regulated by LPS
and overlays with a series of canonical pathways (too
many to be described). The transcription factor E2F1 is in
a central position. This pathway presents several highly
up-regulated genes (dark red), including the transcription
factors USF1 and BMP5. In addition, a series of β-estradiol
related genes were present in this network. This pathway
was correlated with the following functions: cellular
growth and proliferation, cancer, and cellular develop-
ment.
Networks 10 and 11. TNF-α-induced specific genes in the detrusor muscle and bladder mucosa Figure 7
Networks 10 and 11. TNF-α-induced specific genes in the detrusor muscle and bladder mucosa. Microarray 
results were normalized by a robust regression analysis and only genes with an expression above a conditional threshold of 
0.001 (3 SD above background) were selected for analysis. Next, genes presenting a 3-fold ratio in regard to the control group 
were entered as focus genes in Ingenuity Pathway Analysis (IPA) for a core analysis which put the datasets in the context of 
biological processes, pathways, and molecular networks.
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Target validation of BCG-dependent genes by Q-PCR of 
Chromatin Immunoprecipitation (CHIP)-Based Assays
The validity of the predictions of transcriptome analysis
was tested using ChIP-Q-PCR because this is more defini-
tive than confirmation of RNA levels and shows genes that
are being actively transcribed. We selected genes that
appeared to show a clear change from the transcriptome
to be tested by ChIP-Q-PCR. For this purpose, additional
mice were treated with saline or acutely and chronically
with BCG, the urinary bladder was removed and an anti-
body against RNA polymerase II (Abcam) was then used
to precipitate the DNA transcriptome. Q-PCR was per-
formed with primer pairs listed in Table S4 (Additional
File 4). Figure 9 depicts the averaged transcription events
detected per 1000 cells for each gene tested and their
standard deviations. With the exception of SEMA5A,
FVBP1, IGFBP3, and SELE, these results indicate that
chronic treatment with BCG and to a lesser extent acute
BCG induced up-regulation of the following genes as was
predicted by the mRNA-level analysis: ARL6, CSK,
DNAJC5, FAF1, GBP2, GZMA, HLA-DRB1, IL17b, INDO,
MAP3K8, SMAD6, TFEB, VCAM1, and WISP2.
Participation of NF-kappaB in the bladder responses to 
BCG
Because NF-kappaB played a central role in several gene
networks here described, we predicted that BCG induces
NF-kappaB translocation by using EMSA. The results pre-
sented in Figure 10 indicate that chronic BCG indeed
increases the binding of NF-kappaB. To further confirm
this finding, we tested whether the BCG-induced
increased binding of NF-kappaB would lead to up-regula-
tion of transcripts known to possess a p65 binding site.
For this purpose, the human urothelial cancer cell line
(J82) was exposed to BCG or saline for 24 hours and the
cells were frozen and prepared for ChiP-Q-PCR assays. In
this experiment the chromatin was precipitated with a
p65 antibody and the following genes were found to be
up-regulated by BCG: CXCL10, CXCL2, ICAM1, IL-6, and
IL-8 (Figure 11). 
Morphology and immunohistochemistry of urinary 
bladders instilled with BCG-GFP
Because of the large volume (200 μl) of BCG that was
administered in mice relative as compared to humans, we
further investigated whether acute instillation of BCG-
GFP at bladder capacity does not result in urothelial injury
and microscopic extravasation of BCG or would cause
artifacts, including forcing bacteria into the urothelium.
For this purpose, mice were euthanized 24 hours follow-
ing bladder instillation with BCG-GFP, the bladders were
removed and frozen, and were stained with H&E or proc-
essed for fluorescence immunohistochemistry. Figure 12A
is a representative photomicrograph covering the whole
urothelial surface. This is a composite of nine pictures at
original magnification of 200× that was electronically
merged. This picture shows that in our conditions the
instillation of BCG-GFP does not cause any urothelial
Networks 12 and 13. LPS-induced specific genes in the bladder mucosa and detrusor muscle Figure 8
Networks 12 and 13. LPS-induced specific genes in the bladder mucosa and detrusor muscle. Microarray results 
were normalized by a robust regression analysis and only genes with an expression above a conditional threshold of 0.001 (3 
SD above background) were selected for analysis. Next, genes presenting a 3-fold ratio in regard to the control group were 
entered as focus genes in Ingenuity Pathway Analysis (IPA) for a core analysis which put the datasets in the context of biological 
processes, pathways, and molecular networks.
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injury. Figure 12B is a high magnification (400×) of the
dotted black box highlighted in Figure 12A and confirms
the integrity of the urothelial cell layer.
Next, we used fluorescence immunohistochemistry to
demonstrate that, in our laboratory conditions, instilla-
tion of BCG-GFP does not cause any microscopic extrava-
sation of BCG or cause artifacts, including forcing bacteria
into the urothelium. Figures 13A–D are representative
photomicrographs obtained 24 hours after bladder instil-
lation of BCG-GFP. Figure 13A is a DAPI [4',6-diamidino-
2-phenylindole] that was used to highlight the nucleus.
Figure 13B was stained with LRG-47. Figure 13C indicates
the presence of BCG in the urothelium as indicated by the
fluorescence of GFP. It has to be noted that not only fluo-
NF-kappaB electrophoretic mobility shift assays (EMSA) Figure 10
NF-kappaB electrophoretic mobility shift assays 
(EMSA). Anesthetized C57BL6 female mice were instilled 
with 200 μl of one of the following substances: BCG (Thera-
Cys®-Aventis-Pasteur; total dose of 1.35 mg) or pyrogen-free 
saline on days 1, 7, 14, and 21, as described above. Mice were 
euthanized with pentobarbital (200 mg/kg, i.p.) 24 hours after 
a single instillation (BCG acute) or 7 days after 4 weekly 
instillations (BCG chronic). Bladder mucosa nuclear 
extracts were incubated with 2 ng of [32P] NF-kappaB dou-
ble-stranded probe. Supershift reactions were pre-incubated 
for 20 minutes with antibody against p65 or p50. Insert graph 
represents the quantification of p50/p65 NF-kappaB activity 
(indicated by red arrow) using ImageJ Software. Statistical dif-
ferences were determined using GraphPad Software.
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Target validation of selected genes and small GTPases by  ChIP/Q-PCR. Figure 9
Target validation of selected genes and small 
GTPases by ChIP/Q-PCR. Female C57BL/6J mice (n = 20 
per group) were instilled with 200 μl of one of the following 
substances: BCG (total dose of 1.35 mg) or pyrogen-free 
saline on days 1, 7, 14, and 21, as described above. Mice were 
euthanized 24 hours after a single instillation (BCG acute) 
or 7 days after 4 weekly instillations (Control and BCG 
chronic). Bladders were exposed briefly to formaldehyde 
for cross-linking of the proteins and DNA together, followed 
by sonication to fragment the DNA. An antibody against 
RNA polymerase II (Abcam) was then used to precipitate the 
DNA transcriptome. The final ChIP DNAs were then used as 
templates for Q-PCR reactions using primer pairs specific for 
each gene of interest (Table S4; (Additional File 4). Q-PCRs 
were run in triplicate and the averaged Ct values were trans-
ferred into copy numbers of DNA using a standard curve of 
genomic DNA with known copy numbers. The resulting 
transcription values for each gene were also normalized for 
primer pair amplification efficiency using the Q-PCR values 
obtained with input DNA (un-precipitated genomic DNA). 
Results are presented as "transcription events detected per 
1000 cells" for each gene tested. Error bars correspond to 
standard deviations from the triplicate Q-PCR reactions. 
Control represents an un-transcribed region of the genome. 
Asterisks indicate a statistically significant increase (p < 0.05) 
between BCG-treated and control and a pound sign indicates 
a statistically significant decrease (p < 0.05) between BCG-
treated and control.
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rescence if enough for recognition of GFP. The size is also
fundamental since the urinary bladder presents high back-
ground fluorescence. In this context, specific GFP indica-
tive of BCG are highlighted in two areas of the urothelium
contained within white circles (Figure 13C). Small parti-
cles positively labeled with GFP can be noticed in those
areas. In the merged picture, presented in Figure 13D, it
can be appreciated that most of background fluorescence
coincides with DAPI staining (blue) whereas the BCG-
GFP is co-localized in vesicles positives for LRG-47 (yel-
low). White arrows in figures 13A–D point to signals that
are co-localizes in the merge picture (Figure 13D). This set
of figures illustrates also the absence of GFP in any por-
tion of the urinary bladder outside LRG-47 vesicles. Next,
pictures 13B and 13C were submitted to image analysis.
Figure 13E represents the Integrative 3D surface which
translates the luminance of the image in Figure 13B–C as
height for the plot using the nearest neighbor sampling,
next the viewing position of the plot was adjusted for the
nest visualization of the surface plot. The black circles
indicate the central areas of Figure 13B–C with the highest
density of BCG and LRF-47. Next, the co-localization of
BCG-GFP and LRG47-Rhodamine was performed by con-
verting the Figures 13B and 13C to 8-bit gray scale images
(fluorescence intensity range: 0 < 255) using Image J soft-
ware [23], assigned as red and green channels, and the
analysis was performed with the co-localization-finder
plug-in [24]. The results presented in Figure 13F were elec-
tronically generated by the software resulting in a merged
picture with white areas indicating the co-localization
between BCG and LRG-47-positive vesicles. The results
were also automatically tabled and provided the follow-
ing parameters: Pearson's_correlation Rr = 0.0431; over-
lap coefficient R = 0.973628; contribution of red channel
k1 = 2.986; contribution of green channel k2 = 0.371;
slope = 0.0854; intercept = 99.72. Next, the central area of
Figures 13A–D was photographed at high magnification.
The results presented in Figures 13G–J illustrate the find-
ings of the image analysis indicating an almost complete
overlap between BCG and LRG-47 (yellow dots and vesi-
cles in Figure 13J illustrate the image analysis results indi-
cating an overlap R = 0.0973) and that no BCG was found
outside LRG-47-positive vesicles. Since LRG-47 vesicles
are part of the endocytic pathway, it is very unlikely that
the bacterium was mechanically forced into these vesicles.
Together these results indicate that instillation of BCG-
Morphology of the mouse urinary bladder secondary to  rBCG-GFP instillation Figure 12
Morphology of the mouse urinary bladder secondary 
to rBCG-GFP instillation. 1.5 × 107 CFU of GFP-express-
ing rBCG in 200 microliters were instilled into the bladder of 
anesthetized mice, as described in material and methods. 
Twenty-four hours after instillation, the bladder were 
removed and frozen for morphological analyzes. H&E sec-
tions were photographed at 200× (Figure 12A) and 400× 
(Figure 12B). For composite H&E pictures (Fugure 12 A), at 
total of 9 photos were taken at 200× and automatically 
merged in Adobe Photoshop® CS3 extended [89]. Note that 
200 microliters instilled into the bladder of anesthetized mice 
does not disrupt the urothelium integrity.
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BCG-induced increased NF-kappaB activity in J82 human can- cer cell line Figure 11
BCG-induced increased NF-kappaB activity in J82 
human cancer cell line. Human urothelial cancer cell line 
(J82) was exposed to BCG or saline for 24 hours and the 
cells were frozen and prepared for ChiP-Q-PCR assays. In 
this experiment the chromatin was precipitated with a p65 
antibody. The final ChIP DNAs were then used as templates 
for Q-PCR reactions using primer pairs specific for each 
genomic region of interest. Q-PCR was carried out using Taq 
polymerase (iQ SYBR Green Supermix, Bio-Rad). Details of 
the primer sequences and the Genebank accession numbers 
are given in Table S4 (Additional File 4). Results are pre-
sented as "transcription events detected per 1000 cells" for 
each gene tested. Error bars correspond to standard devia-
tions from the triplicate Q-PCR reactions. Control repre-
sents an un-transcribed region of the genome. Asterisks 
indicate a statistical significant difference (p < 0.05) between 
saline- and BCG-treated cells.
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GFP into the mouse bladder, in the conditions described
in this manuscript, does not result in urothelial injury and
microscopic extravasation of BCG or cause artifacts,
including forcing bacteria into the urothelium.
Discussion
The present study was set forth to determine unique genes
modulated by BCG in the bladder target organ apart from
a general inflammatory response. In this context, treat-
Co-localization of BCG-GFP with LRG47-positive vesicles in the mouse bladder urothelium Figure 13
Co-localization of BCG-GFP with LRG47-positive vesicles in the mouse bladder urothelium. Figures 13 A-D are 
representative photomicrographs obtained 24 hours after bladder instillation of BCG-GFP (1.5 × 107 CFU) into the bladder of 
anesthetized mice (see material and methods) and Figures 13 G-J are high magnifications of the same area depicted in Figures 
A-D.  Figures 13 A and 13 G are DAPI [4',6-diamidino-2-phenylindole] that was used to highlight the nucleus. Figures 13B and 
13H were stained with LRG-47. Figures 13C and 13I indicate the presence of BCG in the urothelium as indicated by the fluo-
rescence of GFP in two major areas delimited by white circles. Figures 13D and 13J are merged photograph indicating that 
BCG-GFP is co-localized in vesicles positives for LRG-47 (yellow). White arrows in Figures 13 A-D point to GFP and rhodam-
ine signals that are co-localized in the merge picture (Figure 13D). Next, pictures 13B and 13C were submitted to image anal-
ysis by the Interactive 3D Surface Plot [90], a plug-in for ImageJ software [23]. Figure 13E represents the Integrative 3D surface 
that translates the luminance of the images in Figure 13 B-C as height for the plot using the nearest neighbor sampling. For co-
localization of BCG-GFP and LRG47-Rhodamine, pictures were converted to 8-bit gray scale images (fluorescence intensity 
range: 0 < 255) using Image J software [23] and the analysis was performed with the co-localization-finder plug-in [24]. The 
results presented in Figure 13F were electronically generated by the software resulting in a merged picture with white areas 
indicating the co-localization between BCG and LRG-47-positive vesicles and the Pearson's_correlation and overlap coefficient 
are provided. These results indicate that instillation of BCG-GFP into the mouse bladder, in the conditions described in this 
manuscript, does not result in urothelial injury and microscopic extravasation of BCG or cause artifacts, including forcing bac-
teria into the urothelium.  
LRG-47
E
BCG
AB C D
BCG-GFP LRG-47 DAPI MERGE
F
Pearson’s_Rr = 0.043
Overlap_R = 0.973
G H IJ
BCG-GFP LRG-47 DAPI MERGEBMC Immunology 2008, 9:4 http://www.biomedcentral.com/1471-2172/9/4
Page 12 of 21
(page number not for citation purposes)
ment-specific genes were used to query the IPA in order to
construct molecular networks. Our results indicate that
some unique functions are involved in bladder responses
to BCG. This includes a whole new hypothesis that BCG
interferes with several genes participating in axonal guid-
ance signaling (network 1). The latter includes a family of
small GTPases that along with integrin, protein kinase D1,
PKC, and platelet-derived growth factor regulate axonal
guidance. Although this finding potentially linking BCG
to axonal guidance is unique, activation of small GTPases
genes by intravesical instillation of BCG into the mouse
bladder was just demonstrated by our laboratory [25] and
we extended the results into the present work, indicating
that acute BCG does co-localize with LRG47 vesicles.
However, it remains to be determined whether the same
genes exert axonal guidance properties in the urinary
bladder.
Another unique and exciting finding was that the primary
function of Network 1 was related to the development of
the immune and lymphatic systems, including formation
of lymphoid tissue and Peyer's patches (LTA [26,27] and
VCAM1 [28,29]), size of lymphoid organs (CD86,
PRKCE, and VCAM1 [28]), lymph node development
[LTA [27]], degranulation of the lymphatic system
(PLAUR [30], and CD86), and dilation of lymph vessels
(ELK3) [31]. Our results suggest that BCG induces a series
of genes that may lead to bladder lymphangiogenesis
since their role in the development and function of the
lymphatic system has been established. These included
VCAM1 (vascular cell adhesion molecule 1), a cell surface
glycoprotein implicated in the development of lymphoid
tissues [28] and in a variety of chronic inflammatory con-
ditions, making its expression and function a target for
therapeutic intervention [32]. Interestingly, a role for NF-
kappaB regulating VCAM1 expression has been proposed
[33]. Another gene encodes the LTA (lymphotoxin alpha,
TNF-α superfamily, member 1) which is involved in
Peyer's patch development [26] and is essential for
inflammation-induced lymphangiogenesis. Indeed,
genetic deletion of lymphotoxin beta receptor or lympho-
toxin alpha abrogated development of lymphatic vessels
in the inflamed areas in the thyroid but did not affect
development of neighboring lymphatics [34]. Also LTA
seems to be important in the local lymphoid tissues and
lymph node development [27]. Unlike other cytokines,
lymphotoxin alpha/beta regulates the development of
intestinal lymphoid organs, including Peyer's patches
(PPs) and mesenteric lymph nodes (MLNs). In addition,
intestinal inflammation is suppressed by inhibition of
LTB signaling [35]. A role for LTB signaling has been pro-
posed in initiating immune responses both dependent
and independent of its role in maintaining the organiza-
tion of lymphoid tissues [36]. Coincidently, lymphotoxin
also activates the NF-kappaB pathway [37]. To the best of
our knowledge, there is only a single manuscript indicat-
ing that another bacteria, Mycoplasma pulmonis induces
lymphangiogenesis [38]. Our results suggest that BCG
may have a similar role. It remains to be determined if
alteration of the lymphatic system is part of the beneficial
responses of the bladder to BCG treatment. Another find-
ing of the present work was the participation of BCG-spe-
cific genes in networks involved in the axonal guidance
canonical pathway (Network 1). In addition, Network 3
highlights genes of neuronal origin, including: CDH2 (N-
cadherin), DNAJ35 (a Hsp40 homolog found in axons),
and CTNND2 (catenin or neural plakophilin-related pro-
tein). The combination of these two findings raises the
hypothesis that BCG treatment may impact the nervous
system, possibility explaining its therapeutic role in inter-
stitial cystitis. There are some reports already in the litera-
ture supporting this hypothesis: the immune responses to
BCG mediates axon damage in rodents [39]; bolus injec-
tion of BCG in rats alters the brain vasculature and predis-
poses subjects to thrombosis and hemorrhage [40], and
the supernatant of BCG-stimulated murine peritoneal
macrophages alters neurite development in organotypic
culture [41]. Not surprising, several networks (2, 3, 5, 7,
and 9) overlap with pathways involved in cancer. How-
ever, each one of the cancer networks provides a specific
association of genes and transcription factors that form
hypothesis that can be tested to further determine the role
they might play in the anti-cancer action of BCG. Network
2 has TGFB1 and IL4 driving several genes known to be
involved in cancer development but also known to nega-
tively regulate potentially tissue destructive immune
responses. In contrast, Network 3, which is involved in B
cell receptor signaling, has Akt and P38 MAPk in a central
position. Network 5 has retinoic acid in a central position.
Network 7 has HRAS and NF-kappaB in a central position
and overlaps with the PPAR signaling. Finally, Network 9
has IL6 in a central position and genes such as INDO that
is a known target of IFN-γ. Interestingly, both networks
associated with TNF-α-specific genes (Networks 10 and
11) overlap and have as top functions cancer and cell
death. Regarding the networks associated with LPS-spe-
cific genes (Networks 12 and 13); at least the one found
in the bladder mucosa was associated with the canonical
pathway of LPS/IL1 mediated alterations of nuclear RXR
receptors (including retinoic acid and PPARs). The identi-
fication of these various networks bespeaks the complex-
ity of BCG-induced reactions.
Regarding putative transcription factors (TF), TFEB (Net-
work 4) is known to be expressed in the mouse bladder
urothelium and its activity is increased during bladder
inflammation [39]. In addition, our ChIP-Q-PCR results
confirmed that BCG induces up-regulation of the gene
encoding this TF. Another TF is E2F1 and networks 5 and
13 present this transcription factor in a central position.BMC Immunology 2008, 9:4 http://www.biomedcentral.com/1471-2172/9/4
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Interestingly, an E2F1-dependent increase in transcription
was found in U1 bladder cancer cells emerging from qui-
escence upon serum stimulation [42]. E2F1 promoter
activity in quiescent cells was associated with recruitment
of NF-kappaB. NF-kappaB was replaced largely by E2F1 in
concert with gene activation during the early stage (12 h)
of serum stimulation. The finding that NF-kappaB is
expressed in a central position in several inflammatory
networks (1, 7, 10, and 12), corroborates with the pro-
posed role of NF-kappaB as a link between chronic
inflammation and cancer [43]. NF-kappaB seems to play
a major role in gene regulation in urothelial cells and sev-
eral recent studies reveal a role for NF-kappaB on the
responses of these cells to BCG [12,44,45]. Indeed, BCG
induced IL-6 expression by human transitional cell neo-
plasms requires NF-kappaB and AP-1 [46,47]. Others
have presented evidence that BCG activates nuclear trans-
location of the transcription factor NF-kappaB, since pre-
treatment of with sulfasalazine, an inhibitor of NF-
kappaB activity, blocked the ability of BCG to induce IL-8
secretion [48,49]. Others have shown that BCG induces
CXCL8 production in epithelial cells by a mechanism
involving NF-kappaB [50]. Finally, several laboratories
have provided additional evidence of NF-kappaB involve-
ment in urinary bladder cancer [51] and the benefits of
drugs derived from curcumin, an inhibitor of NF-kappaB
[52]. Recently, a functional insertion/deletion polymor-
phism has been identified in the promoter region of
NFKB1 that is being proposed as a useful marker for the
identification of patients with high risk of recurrence of
superficial bladder cancer [53]. Our present findings using
EMSA and ChIP-Q-PCR confirmed that both the mouse
urinary and the J82 urothelial cancer cell line respond to
BCG treatment with an increased translocation of NF-kap-
paB.
The results here presented have to be taken in light of the
choices made to provide a manageable focus for this
paper. This study was carried out at a single time point.
We understand that this time point may not identify pre-
ceding or proceeding events as we indicated previously
[54-56]. Therefore, the results of regulatory network here
presented should be viewed as a snapshot of the bladder
transcriptome. Nevertheless, genes identified as impor-
tant at this time point can now be followed over time by
other techniques. The study also focused on the responses
that are unique to BCG, which loses sight of the larger pic-
ture of the response common to all three stimuli of
inflammation. The common pathways have been consid-
ered previously [56,57]. Another short coming of this type
of analysis was to exclude initially genes that are com-
monly up-regulated by the 3 different stimuli. The ration-
ale for the latter was to focus the study on genes
specifically regulated by BCG in contrast to the other stim-
uli. By doing this, we did not discuss or further analyze the
common genes involved in bladder responses to inflam-
mation. Although genes responding to more than one
treatment were not considered, when treatment-specific
genes were assembled in molecular networks, the network
themselves shared some overlap of functions.
One of the family of genes induced specifically by BCG in
the bladder mucosa belong to small GTPases (Network 1)
and GBP2 on Network 2. These results confirmed our
recent reports using suppressive subtraction hybridization
that the small GTPases are upregulated in the bladder
mucosa in response to BCG [25]. Here we went further to
verify whether BCG-GFP co-localizes with one of the
small GTPases. Indeed, our results indicate that BCG-GFP
has almost 100% coincidence with LRG-47-positive vesi-
cles (Figure 13). The association of p47 GTPases with
membranous compartments such as the endoplasmic
reticulum and the Golgi, implicate these molecules in
intracellular membrane trafficking or processing [58] and
that mechanical stimuli alone could not be responsible
for our findings. In addition, products of these genes are
known to coordinate cellular defense against intracellular
pathogens such as Mycobacteria [59,60], possibly by pro-
moting acidification of the phagosome [61] and elimina-
tion of the intracellular pathogen [62]. p47 GTPases are
one of the most effective cell-autonomous resistance sys-
tems known against intracellular pathogens in the mouse
[60,61], and have been shown to be essential for immune
control in vivo of Listeria monocytogenes, Toxoplasma gondii,
and  Mycobacterium tuberculosis (Mtb) [63]. In addition,
mice lacking LRG-47 failed to control Mtb  replication
[63]. Thus, LRG-47 may serve as a critical vacuolar traffick-
ing component used to dispose of intracellular pathogens
like Mtb [63]. Therefore, it is expected that this group of
GTPases may limit the activity and survival of BCG in the
mouse bladder. In addition to limiting BCG activity, this
group of GTPases is part of the inflammatory response. In
particular, human GBP-1 and GBP-2 modulate the
endothelial cell responses to inflammatory cytokines
[64,65]. Taken together, these results suggest that in the
case of BCG vaccine, these GTPases may act as a control-
led-release mechanism for the agent infecting the bladder.
The question arises as to the relevance of these findings to
the clinical use of BCG and particularly whether the
response of normal urothelium to BCG is relevant to can-
cer treatment. First, the major difference is that the mice
used in the present work do not have cancer, and, there-
fore, our results are most relevant to the response of the
bladder to BCG and provide no information on cancer-
specific responses. A second potential difference is
whether the larger volume of BCG administered relative
to bladder volume in these mice as compared to human
clinical use might cause artifacts, including forcing bacte-
ria into the urothelium. Our previous studies using pres-BMC Immunology 2008, 9:4 http://www.biomedcentral.com/1471-2172/9/4
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sure monitoring showed that at 0.2 ml, the pressure was
less than 10% of that required to produce overdistention.
The literature is remarkably mute on the presence of BCG
within the urothelium within 24 hours of administration,
and studies that reported on the absence of BCG in the
bladder were performed a week after BCG administration,
well after the responses documented here occurred and
after much of the urothelium had sloughed [66,67]. We
suggest that a deeper understanding of the sequence of the
response of humans with bladder cancer treated with BCG
may require biopsies within 24–48 hours to determine
whether BCG enters the urothelium and then produces
responses similar to those that occur in the mouse urothe-
lium reported here. However, it is not practical to biopsy
a human being, 24 hours after administering BCG. In this
context, the animal model here described, with all its lim-
itations, can facilitate investigations of the basic processes
and mechanisms involved in urinary bladder responses to
intravesical BCG instillation.
Conclusion
In conclusion, the present research approach identified
genes involved in the responses to intravesical BCG ther-
apy in the bladder target organ apart from those involved
in the responses to LPS and TNF-α and suggested novel
mechanisms involved in the responses to BCG. The major
findings of the present work suggest that BCG is involved
in the development and function of immune system and
lymphatic vessels. Interestingly, the present work con-
firms our recent findings [25] that BCG also up-regulates
genes encoding several small GTPases, such as LRG47 [25]
that are responsible for an organism's defense to intracel-
lular pathogens. It remains to be determined whether
over-expression of small GTPases would limit the survival
of BCG within the urinary bladder or whether it will con-
tribute to a controlled-release mechanism for the agent
infecting the bladder.
Methods
Animals
All animal experimentation described here was performed
in conformity with the "Guiding Principles for Research
Involving Animals and Human Beings" (OUHSC Animal
Care & Use Committee protocol #05-081I and 05-088).
Ten to twelve week-old C57BL/6 female mice (The Jack-
son Laboratory; Bar Harbor, ME) were anesthetized,
transurethrally catheterized as previously described, and
instilled with 200 μl at a pressure not exceeding 5 cmH20.
Using this procedure in previous experiments, we found
no evidence of disruption of urothelial layers due to over
distention [19,22,25,57,68-70]. Mice were instilled with
one of the following substances: BCG (TheraCys®-Aventis-
Pasteur; total dose of 1.35 mg [71]), E. coli LPS (strain
055:B5; 100 μg/ml [55,56,72], TNF-α (1 μg/ml) [19], or
pyrogen-free saline on days 1, 7, 14, and 21. Seven days
after the last instillation, mice were euthanized with
pentobarbital (200 mg/kg, i.p.), and the bladders
removed, placed in RNA later™ (Ambion) and visualized
under a dissecting microscope (Nikon SMZ 1500). As pre-
viously described [57], the urothelium along with the sub-
mucosa were separated from the detrusor muscle and
used in subsequent experiments.
Minimum Information About Microarray Experiments – 
MIAME [73]
Objective
To determine the time course of gene-expression in uri-
nary bladders in response to chronic intravesical instilla-
tion of saline, BCG, TNF-α, or LPS.
Array design
Mouse plastic 5 K Arrays (Clontech, Palo Alto, CA, Cat.
#634809). For a complete list of genes present in this
array see reference [74].
Animal Numbers
This experiment involved: twelve mice per group; three
different biological replicates; four treatments: saline,
BCG, TNF-α, and LPS; and two tissue layers: urothelium/
submucosa and detrusor muscle; for a total of 288 mice.
Sample preparation for cDNA Expression Arrays
We used the same technology as we described before
[54,56,75-77]. Briefly, the bladder mucosa (n = 12) and
the detrusor muscle (n = 12) of the bladders from each
group were homogenized together in Ultraspec RNA solu-
tion (Biotecx Laboratories Inc. Houston, TX) for isolation
and purification of total RNA. Three biological replicates
were used per group. RNA was DNase-treated according to
manufacturer's instructions (Clontech Laboratories, Palo
Alto, CA), and the quality of 10 μg was evaluated by dena-
turing formaldehyde/agarose gel electrophoresis. RNA
yielded a ratio 260/280 > 1.8, relatively intact ribosome
RNA, and minimum low molecular weight degradation.
Mouse cDNA Expression Arrays
cDNA probes were prepared from DNase-treated RNAs
obtained from each of the experimental groups. Five μg of
DNase-treated RNA was reverse-transcribed to cDNA and
labeled with [α-33P]dATP, according to the manufacturer's
protocol (Clontech, Palo Alto, CA). The radioactively
labeled complex cDNA probes were hybridized overnight
to Atlas™ mouse plastic 5 K arrays (Clontech, Palo Alto,
CA) using ExpressHyb™ hybridization solution with con-
tinuous agitation at 68°C. After two high-stringency
washes, the hybridized membranes were exposed (at
room temperature) to a ST Cyclone phosphor screen over-
night. Spots on the arrays were quantified by BD AtlasIm-
age™ 2.7 software (Clontech, Palo Alto, CA).BMC Immunology 2008, 9:4 http://www.biomedcentral.com/1471-2172/9/4
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Array normalization
Normalization among array experiments was based on
the fact that spot intensities from genes not expressed by
biological specimens constitute noise and are therefore
randomly distributed. The method models the signals
from non-expressed genes to a normal distribution using
an iterative nonlinear curve fitting procedure. A two-step
normalization procedure was performed, as described
[77]. The first step was the determination of the parame-
ters of the background of the array – average (Av) and
standard deviation (SD) of normally distributed low level
expressions in the array. A normalized score, "S," was
obtained [S = (PV - Av)/SD], where PV is the original pixel
value for the spot, and Av and SD are the mean and stand-
ard deviation of the set of background spots. In the nor-
malized array, the distribution of S has mean of zero and
SD = 1 over the set of background genes [77]. We accepted
all genes expressing 3 SDs above the mean background
that were used for "adjustment" as described below.
Adjustment of the normalized profiles to each other by a robust 
regression analysis
In this analysis potential outliers were identified and their
contribution to the calculations down-weighted in an iter-
ative manner. All expression profiles of both control and
treated groups were then re-scaled to the averaged control
group. Outliers were thereafter, determined as having
deviations not associated with the normal distribution.
Robust regression analyses was used to exclude the influ-
ences of potential outliers [77]. Only genes that were
expressed 3 SDs above the average were submitted to fur-
ther analysis and the ratio of gene-expression between
LPS-, TNF-, BCG- and saline-challenge was obtained.
Genes expressing a ratio greater than 3.0 were selected and
classified as BCG-, TNF-, and LPS-specific genes. Those
genes whose expression was altered by more than one
stimulus were not considered for the purpose of this
paper.
Development of the observed interactome of bladder 
mucosa and detrusor specific genes
The accession number and the ratio (treated/saline) for
each mucosa- and detrusor-gene whose expression was
altered by at least 3-fold by each stimuli were uploaded as
focused genes in the Ingenuity Pathways Analysis [IPA],
(Ingenuity Systems, Mountain View, CA), as described
[69]. IPA is a robust and expertly curated database con-
taining up-to-date information on over 20,000 mamma-
lian genes and proteins, 1.4 million biological
interactions, and one hundred canonical pathways incor-
porating over 6,000 discreet gene concepts. This informa-
tion is integrated with other relevant databases such as
EntrezGene and Gene Ontology [20,78]. IPA computes a
score for each network according to the fit of the set of
supplied focus genes (BCG-, TNF-, and LPS-dependent
genes). These scores, derived from p values, indicate the
likelihood of focus genes to belong to a network versus
those obtained by chance. A score >2 indicates a ≥ 99%
confidence that a focus gene network was not generated
by chance alone [20]. Mathematically, the score is simply
the negative exponent of the p-value calculation. For
example, if the score is 3, then the corresponding p-value
was 10-3, i.e. there is a 1 in 1000 chance that the Network
Eligible Molecules found in that network appeared there
just by chance. The experimental datasets of stimulus-
dependent genes was used to query the IPA and to com-
pose a set of interactive networks taking into considera-
tion canonical pathways, the relevant biological
interactions, and the cellular and disease processes.
Chromatin immunoprecipitation (CHIP) quantitative real-
time polymerase chain reaction (Q-PCR)-Based Assays
To determine whether intravesical BCG treatment would
alter bladder cytokine gene expression, we used chroma-
tin immunoprecipitation combined with Q-PCR. For this
purpose, female C57BL/6J mice were anesthetized and
instilled with 200 μl of one of the following substances:
BCG (TheraCys®-Aventis-Pasteur; total dose of 1.35 mg)
or pyrogen-free saline on days 1, 7, 14, and 21, as
described above. Mice were euthanized with pentobarbi-
tal (200 mg/kg, i.p.) 24 hours after a single instillation
(BCG acute) or 7 days after 4 weekly instillations (BCG
chronic). A total of 60 mice were used (20 mice per
group). Bladders were removed rapidly, frozen, and were
shipped to Genpathway [79] for querying the chromatin
for gene transcription (Genpathway's TranscriptionPath
Query assay) [80].
The urinary bladders were exposed briefly to formalde-
hyde for cross-linking of the proteins and DNA together,
followed by sonication to fragment the DNA into pieces
of approximately 300–500 base pairs. An antibody
against RNA polymerase II (Abcam) was then used to pre-
cipitate the DNA transcriptome. The Ab-protein-DNA
complexes were purified using beads coupled to protein
A. The DNA was isolated from the complexes using a com-
bination of heat to reverse cross-linking, RNase and pro-
teases, and then purified using phenol extraction and
EtOH precipitation. The final CHIP DNAs were then used
as templates in quantitative PCR reactions using primer
pairs specific for each gene of interest. Quantitative PCR
was carried out using Taq polymerase (iQ SYBR Green
Supermix, Bio-Rad). Primer pairs were designed using
Primer 3 [81]. Details of the primer sequences are given in
Table S4 (Additional File 4). The designed primers shared
100% homology with the target sequence but no signifi-
cant homology with other sequences.
Q-PCRs were run in triplicate and the values were trans-
ferred into copy numbers of DNA using a standard curveBMC Immunology 2008, 9:4 http://www.biomedcentral.com/1471-2172/9/4
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of genomic DNA with known copy numbers. The result-
ing transcription values for each gene were also normal-
ized for primer pair amplification efficiency using the Q-
PCR values obtained with Input DNA (unprecipitated
genomic DNA). Results are presented as Transcription
Events Detected Per 1000 Cells for each gene tested.
Statistical Analysis – Q-PCR
The difference between two mean values was analyzed
with an unpaired Student's t-test (GraphPad Prism soft-
ware version 4.0; GraphPad Software, Inc. San Diego,
CA). A nominal p value less than 0.05 was considered sta-
tistically significant.
Electrophoretic mobility shift assays (EMSA)
Anesthetized C57BL6 female mice were instilled with 200
μl of one of the following substances: BCG (TheraCys®-
Aventis-Pasteur; total dose of 1.35 mg) or pyrogen-free
saline on days 1, 7, 14, and 21, as described above. Mice
were euthanized with pentobarbital (200 mg/kg, i.p.) 24
hours after a single instillation (BCG acute) or 7 days after
4 weekly instillations (BCG chronic). Urinary bladders
were placed in cold phosphate buffered saline (0°C), con-
taining protease inhibitors (Protease Inhibitor Cocktail,
Sigma, St. Louis, MO) and phosphatase inhibitors (20
mM sodium fluoride, 1 mM β-glycerophosphate, and 1
mM sodium orthovanadate).
The detrusor muscle presents a high level of complexity
which makes difficult the interpretation of transcriptional
factor binding results [22]. To decrease the complexity of
using whole bladder homogenates, the bladder mucosa
was separated from the detrusor smooth muscle, as
described [22,68]. Briefly, immediately after removal
from the animal, bladders were placed in PBS with pro-
tease inhibitors on ice and visualized under a dissecting
microscope (Nikon SMZ 1500) and the detrusor smooth
muscle was separated by blunt dissection away from the
mucosa which contained the epithelium and sub-epithe-
lial layers. Isolated layers were flash frozen and stored at -
80°C until processing. Tissues were pulverized in a spring-
loaded tissue pulverizer (Bio-Pulverizer, Biospec Prod-
ucts, Bartlesville, OK) chilled with liquid nitrogen.
Nuclear and cytosolic extracts were prepared using the
Pierce NE-PER Kit that enables stepwise separation and
preparation of cytoplasmic and nuclear extracts from
bladder tissue. Addition of the first two reagents (Pierce's
proprietary information) to the pulverized tissue causes
disruption of cell membranes and release of cytoplasmic
contents. After recovering the intact nuclei from the cyto-
plasmic extract by centrifugation at 16,000 × g for 5 min-
utes, the nuclei are lysed with a third reagent (Pierce's
proprietary information) to yield the nuclear extract.
Extracts obtained with this product generally have less
than 10% contamination between nuclear and cytoplas-
mic fractions-sufficient purity for most experiments
involving nuclear extracts. A western blot was prepared
using the nuclear and cytosolic extracts and probed for the
nuclear proteins histone H3 and lamin A/C. No nuclear
contamination was shown in the cytosolic fractions (data
not shown). Protein concentrations were determined with
a Micro BCA Kit (Pierce, Rockford, IL) per manufacturer's
instructions.
NF-kappaB EMSA
A double-stranded NF-kappaB probe, 5' AGT TGA GGG
GAC TTT CCC AGG 3' (Promega, Madison, WI), was end-
labeled with [γ-32P] ATP (3000 Ci/mmole; GE Healthcare)
and T4 polynucleotide kinase (New England Biolabs),
and then purified using a G-50 column (GE Healthcare).
Nuclear extracts (10 μg) were incubated with 2 ng of [32P]
NF-kappaB double-stranded probe in a final volume of 20
μl containing 10 mM Tris HCl pH 8.0, 50 mM KCl, 1 mM
DTT, 0.5 mM EDTA, 0.5% Triton X-100, 12.5% glycerol,
and 1 μg poly d(I-C). For competition reactions, a 50-fold
excess of unlabelled NF-kappaB probe was added to the
reaction mixture, and it was incubated at room tempera-
ture for 10 minutes before the addition of the [32P] NF-
kappaB double-stranded probe. Supershift reactions were
pre-incubated for 20 minutes with antibody against p65
or p50 (p65, sc-109X, and p50, sc-114X, Santa Cruz Bio-
technology, Santa Cruz, CA). Reaction mixtures were
incubated for 30 minutes at room temperature. DNA-pro-
tein complexes were resolved on a non-denaturing 5%
polyacrylamide gel at 1 mA/cm2 2.5 hours in 0.5 TBE (45
mM Tris-borate and 1 mM EDTA). Gels were vacuum-
dried and visualized on Kodak Biomax MS Film and
quantified using ImageJ Software (NIH) and statistical dif-
ferences were determined using GraphPad (version 4.0;
GraphPad Software, Inc., San Diego, CA).
Target validation by Q-PCR of Chromatin Immunoprecipitation 
(CHIP)-Based Assays
Target validation was sought for genes known to have a
binding site for NF-kappaB p65. For this purpose, the
respective gene accession was uploaded into PAINT [Pro-
moter Analysis and Interaction Network Toolset; [82]] to
query the TRANSFAC database [83]. For target validation,
human urothelial cancer cell line (J82) was challenged
with saline or BCG for 24 hours, a p65 antibody (sc-109,
rabbit polyclonal, Santa Cruz Biotehcnology) was used to
precipitate the chromatin, and ChiP-Q-PCR was used to
quantify the message for p65-dependent genes.
Human Urothelial Cell Culture
Human bladder carcinoma cell line J82 (HTB-1) was
obtained from the American Tissue Culture Collection.
J82 cells were seeded onto a 4-chamber slide and cultured
in Minimum Essential Media (MEM) supplemented with
10% fetal bovine serum (FBS), 100 μM non-essentialBMC Immunology 2008, 9:4 http://www.biomedcentral.com/1471-2172/9/4
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amino acids, 1 mM sodium pyruvate, 100 U/ml penicil-
lin/streptomycin and 2× MEM Vitamin Solution. Cells
were maintained at 37°C in a humidified atmosphere
containing 5% CO2 until 90% confluence was reached.
The medium was removed and cells were fixed in 4% for-
maldehyde.
Challenge of J82 with BCG and ChIP generation
For this purpose, cells were cultured in 75 cm2 flasks (10
ml media/1 ml cells), starved overnight using MEM, and
challenged for 24 hours with control saline or BCG (8.1 ×
106 colony forming units [CFU]). Following 24 hours of
challenge, 106 cells from both groups were frozen for
ChIP-Q-PCR and shipped to Genpathway [79] for query-
ing the chromatin for detection and quantification of p65
binding upstream of specific genes using chromatin
immunopreciptation (ChIP) combined with real time
PCR (Q-PCR) (Genpathway's FactorPath Query assay)
[80]. J82 cells were exposed briefly to formaldehyde for
cross-linking of the proteins and DNA together, followed
by sonication to fragment the DNA into pieces of approx-
imately 300–500 bp. A p65 antibody (sc-109, Santa Cruz
Biotechnology) was then used to precipitate the p65-DNA
complexes. The Ab-protein-DNA complexes were purified
using beads coupled to protein G. The DNA was isolated
from the complexes using a combination of heat to
reverse cross-linking, RNase and proteases, and then puri-
fied using phenol extraction and EtOH precipitation. The
final ChIP DNAs were then used as templates for Q-PCR
reactions using primer pairs specific for each genomic
region of interest. Q-PCR was carried out using Taq
polymerase (iQ SYBR Green Supermix, Bio-Rad). Primer
pairs were designed using Primer 3 [81]. Details of the
primer sequences and the Genebank accession numbers
are given in Table S4 (Additional File 4). The designed
primers shared 100% homology with the target sequence
but no significant homology with other sequences.
Q-PCR
Q-PCR reactions were run in triplicate and the averaged Ct
values were transferred into copy numbers of DNA using
a standard curve of genomic DNA with known copy num-
bers. The resulting binding values for each genomic region
were also normalized for primer pair amplification effi-
ciency using the Q-PCR values obtained with Input DNA
(un-precipitated genomic DNA). Results are presented as
binding events detected per 1000 cells for each genomic
region tested and compared to an un-transcribed region
used as a negative control. The difference between two
mean values was analyzed with an unpaired Student's t-
test (GraphPad Software, Inc., San Diego, CA). A nominal
p value less than 0.05 was considered statistically signifi-
cant.
Co-localization of BCG-GFP with LRG47 in the mouse bladder 
urothelium
Recombinant Mycobacterium bovis bacillus Calmette-
Guerin expressing green fluorescent protein (rBCG-GFP),
was constructed and provided by Dr. Michael O'Donnell
[84,85]. rBCG-GFP was plated on Middlebrook 7H10
Bacto agar (Difco) supplemented with 10% ADC and 30
mg of kanamycin per ml. Individual colonies showing
bright green fluorescence under illumination from a long-
wavelength UV lamp were picked and grown in BCG cul-
ture medium for the internalization studies [84,85]. Cells
were grown in flat-bottomed six-well tissue culture plates
(Nunc) containing RPMI 1640 medium (Gibco BRL) sup-
plemented with 10% heatinactivated fetal bovine serum
and 30 mg of kanamycin per ml. When the cell density
reached approximately 70% confluence, the monolayer
cells were washed once with culture medium, and 1.5 ×
107 CFU of GFP-expressing rBCG in 200 microliters were
instilled into the bladder of anesthetized mice, as
described above. Twenty-four hours after instillation, the
bladders were removed and frozen for morphological
analyses.
Morphology of the mouse urinary bladder secondary to rBCG-GFP 
instillation
Frozen bladders were processed for routine immunohisto-
chemistry according to published methods [22,86]. Fro-
zen sections were post-fixed in 1% formaldehyde. All
reagent incubations and washes were performed at room
temperature and routine H&E sections and immunofluo-
rescence were performed. For the latter, 5% normal don-
key blocking serum (Jackson Immunolabs) was placed on
all slides for 45 min and sections were incubated with pri-
mary antibody for 1 hour and 45 minutes in a humidified
chamber. Slides were washed 3 × 5 minutes in PBS and
incubated with secondary antibodies. Slides were washed,
counterstained with DAPI (1:20,000 dilutions of 10 mg/
ml) for 2 minutes and coverslipped with Shur/Mount
(TBS) mounting media and sealed with nail polish. All tis-
sue sections were visualized using a Nikon inverted fluo-
rescent microscope (Eclipse TE2000 coupled with epi-
fluorescence attachment) [87] and imaged at room tem-
perature using a FC9900 Cooled camera (Kodak chip:
KAF3200ME w/microlens technology and 4-million pix-
els in a 2184 × 1472 array; F2.8 manual zoom lens and
F1.4 fixed lens) driven by NIS-Elements AR2.3 Imaging
software (Laboratory Imaging/Nikon) [88]. The LRG47
(A19) antibody (Santa Cruz Biotech) was used at 1:50
dilution. Secondary antibody, donkey anti-rabbit IgG
AF488 conjugate (Molecular Probes; http://probes.invit
rogen.com), was used at 1:400 dilution. Control included
omission of the primary antibody.BMC Immunology 2008, 9:4 http://www.biomedcentral.com/1471-2172/9/4
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Image analyses
H&E sections were photographed at 200× and 400×. For
composite H&E pictures, at total of 9 photos were taken at
200× and automatically merged in Adobe Photoshop®
CS3 extended [89]. For immunofluorescence, on the fluo-
rescence microscope, the background fluorescence (non-
specific fluorescence of the tissue) of each image was set
to a barely detectable level by adjusting the gain of the
charge-coupled device camera, and then the image was
captured. To determine the peak of fluorescence intensity,
RGB images (BCG-GFP, and LRG47) were placed in the
same canvas using Adobe Photoshop® CS3 extended [89]
and were analyzed using Image J software [23] using an
Interactive 3D Surface Plot [90]. The Integrative 3D sur-
face translates the luminance of an image as height for the
plot. Internally, the image is scaled to a square image
using nearest neighbor sampling, next the viewing posi-
tion of the plot was adjusted for the nest visualization of
the surface plot. For co-localization of BCG-GFP and
LRG47-Rhodamine, pictures were converted to 8-bit gray
scale images (fluorescence intensity range: 0 < 255) using
Image J software [23] and the analysis was performed with
the co-localization-finder plug-in [24]. The results are pre-
sented in an electronically merged picture with white
areas indicative of co-localization and the results were
automatically tabled with computer Pearson's correlation,
overlap coefficient, contribution of both channels to over-
lap coefficient, slope and intercept of the linear regression,
% pixels selected, min and max in both channels.
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